There are 22 papers on urologic disease in aging research: 17 observational studies in people, 3 in animals, 2 reviews.
1 new paper in 30 daysSee all 31 papers on urologic disease
“Urinary system diseases contribute significantly to the prediction of impaired function.”
- Humans17
- Animals3
- In silico1
Effects
2Health-related quality of life
downin humans1
1 study
Health-related quality of life
downin humans1
Urologic disease is linked with lower health-related quality of life in humans (rural community-dwellers) (β = -0.05, 95% CI = -0.09, -0.02).
“followed by those with urinary diseases (β = - 0.05; 95% CI = - 0.09, - 0.02) and stroke (β = - 0.05; 95% CI = - 0.09, - 0.01).”
Humansrural community-dwellers
Comorbidities and health-related quality of life among rural older community-dwellers in Vietnam
PloS one
Sarcopenia
upin humans1
1 study
Sarcopenia
upin humans1
Urologic disease induces sarcopenia in humans.
“urologic diseases cause sarcopenia”
Review
Advances in sarcopenia and urologic disorders
Frontiers in nutrition
Associations
3Everyday functional impairment
upin humans1
1 study
Everyday functional impairment
upin humans1
Urologic disease predicts everyday functional impairment in humans (hospitalized older patients with schizophrenia).
“Urinary system diseases contribute significantly to the prediction of impaired function.”
Humanshospitalized older patients with schizophrenia75% femalesn = 113
Frontiers in psychiatry
Male sex
upin dogs1
1 study
Male sex
upin dogs1
male sex raises the risk of urologic disease in dogs.
“The prevalence of cardiovascular and urinary disease was significantly higher in males”
Animalsmalesn = 269
Morbidity and mortality in elderly dogs - a model for human aging
BMC veterinary research
Ozone
upin humans1+0.3%
1 study
Ozone
upin humans1+0.3%
Ozone is linked with a higher risk of urologic disease in humans (+0.29%).
“0.29 % from urinary system disease”
Humans10-μg/m3 increase in lag 0-1 daylag 0-1 day
Environment international
Trial sponsors
Company3 trialsPhase 35,368 people
Novartis Pharmaceuticals Corporation
Company1 trialPhase 3220 people
Company1 trialPhase 214 people
Company2 trialsPhase 1/299 people
Company1 trialPhase 1/25,000 people
Company1 trialPhase 15,000 people
Company1 trial208 people
2 trialsPhase 4176 people